Eisai

Eisai Co., Ltd., commonly referred to as Eisai, is a Japanese multinational pharmaceutical company headquartered in Tokyo. Founded in 1941, Eisai develops, manufactures, and markets medicines and vaccines for human health care. The company emphasizes a long-standing corporate philosophy called Human Health Care (hhc), which centers on addressing unmet medical needs and improving patient quality of life.

Eisai's products span several therapeutic areas, with a strong focus on neurology and oncology. Notable medicines include Lenvima (lenvatinib), a kinase inhibitor approved for various cancers and thyroid disease; Fycompa (perampanel), an antiepileptic drug; and lecanemab (brand name Leqembi), a disease-modifying therapy for Alzheimer's disease developed in collaboration with Biogen and approved in the United States in 2023. Eisai maintains an extensive research and development network worldwide, pursuing neuroscience, oncology, and immunology.

The company operates globally, with facilities and R&D in Asia, the Americas, and Europe. It is listed on the Tokyo Stock Exchange and maintains partnerships and licensing agreements to advance its portfolio. Eisai has pursued collaborations to supplement internal development, including joint programs with Biogen on Alzheimer's disease. As part of its strategy, Eisai seeks to balance medicine development with sustainability and responsible corporate governance.